COVID-19 through adverse outcome pathways: Building networks to better understand the disease – 3rd CIAO AOP Design Workshop

Main Article Content

Laure-Alix Clerbaux , Núria Amigó, Maria João Amorim, Anna Bal-Price, Sofia Batista Leite, Anna Beronius, Gillina F. G. Bezemer, Ann-Charlotte Bostroem, Annamaria Carusi, Sandra Coecke, Rachel Concha, Evangelos P. Daskalopoulos, Francesca De Bernardi, Eizleayne Edrosa, Steve W. Edwards, Julija Filipovska, Natàlia Garcia-Reyero, Felicity N. E. Gavins, Sabina Halappanavar, Alan J. Hargreaves, Helena T. Hogberg, Mylène T. Huynh, Daniel Jacobson, Jonathan Josephs-Spaulding, Young Jun Kim, Hyun Joon Kong, Catharine E. Krebs, Ann Lam, Brigitte Landesmann, Adrienne Racanelli Layton, Yong Oh Lee, Donna S. Macmillan, Alberto Mantovani, Luigi Margiotta-Casaluci, Marvin Martens, Rosalinde Masereeuw, Sally A. Mayasich, Liang Merlin Mei, Holly Mortensen, Amalia Munoz Pineiro, Penny Nymark, Elan Ohayon, Joshi Manoj Ojasi, Alicia Paini, Nikolaos Parissis, Surat Parvatam, Francesca Pistollato, Magdalini Sachana, Jorid Birkelund Sørli, Kristie M. Sullivan, Jukka Sund, Shihori Tanabe, Katya Tsaioun, Mathieu Vinken, Laura Viviani, Jennifer Waspe, Catherine Willett, Clemens Wittwehr
[show affiliations]

Abstract

On April 28-29, 2021, 50 scientists from different fields of expertise met for the 3rd online CIAO workshop. The CIAO project “Modelling the Pathogenesis of COVID-19 using the Adverse Outcome Pathway (AOP) framework” aims at building a holistic assembly of the available scientific knowledge on COVID-19 using the AOP framework. An individual AOP depicts the disease progression from the initial contact with the SARS-CoV-2 virus through biological key events (KE) toward an adverse outcome such as respiratory distress, anosmia or multiorgan failure. Assembling the individual AOPs into a network highlights shared KEs as central biological nodes involved in multiple outcomes observed in COVID-19 patients. During the workshop, the KEs and AOPs established so far by the CIAO members were presented and posi­tioned on a timeline of the disease course. Modulating factors influencing the progression and severity of the disease were also addressed as well as factors beyond purely biological phenomena. CIAO relies on an interdisciplinary crowd­sourcing effort, therefore, approaches to expand the CIAO network by widening the crowd and reaching stakeholders were also discussed. To conclude the workshop, it was decided that the AOPs/KEs will be further consolidated, inte­grating virus variants and long COVID when relevant, while an outreach campaign will be launched to broaden the CIAO scientific crowd.

Article Details

How to Cite
Clerbaux, L.-A., Amigó, N., Amorim, M. J., Bal-Price, A., Batista Leite, S., Beronius, A., Bezemer, G. F. G., Bostroem, A.-C., Carusi, A., Coecke, S., Concha, R., Daskalopoulos, E. P., De Bernardi, F., Edrosa, E., Edwards, S. W., Filipovska, J., Garcia-Reyero, N., Gavins, F. N. E., Halappanavar, S., Hargreaves, A. J., Hogberg, H. T., Huynh, M. T., Jacobson, D., Josephs-Spaulding, J., Kim, Y. J., Kong, H. J., Krebs, C. E., Lam, A., Landesmann, B., Layton, A., Lee, Y. O., Macmillan, D. S., Mantovani, A., Margiotta-Casaluci, L., Martens, M., Masereeuw, R., Mayasich, S. A., Mei, L. M., Mortensen, H., Munoz Pineiro, A., Nymark, P., Ohayon, E., Ojasi, J., Paini, A., Parissis, N., Parvatam, S., Pistollato, F., Sachana, M., Sørli, J. B., Sullivan, K. M., Sund, J., Tanabe, S., Tsaioun, K., Vinken, M., Viviani, L., Waspe, J., Willett, C. and Wittwehr, C. (2022) “COVID-19 through adverse outcome pathways: Building networks to better understand the disease – 3rd CIAO AOP Design Workshop”, ALTEX - Alternatives to animal experimentation, 39(2), pp. 322–335. doi: 10.14573/altex.2112161.
Section
Meeting Reports
References

Bezemer, G. F. G. and Garssen, J. (2021). TLR9 and COVID-19: A multidisciplinary theory of a multifaceted therapeutic target. Front Pharmacol 11, 601685. doi:10.3389/fphar.2020.601685

Byrne, A. W., McEvoy, D., Collins, A. B. et al. (2020). Inferred duration of infectious period of SARS-CoV-2: Rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open 10, e039856. doi:10.1136/bmjopen-2020-039856

Datta, S. D., Talwar, A. and Lee, J. T. (2020). A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection illness beyond acute infection and public health implications. JAMA 324, 2251-2252. doi:10.1093/cid/ciaa1280

Kim, Y., Park, C., Lim, S. et al. (2021). Advanced adverse outcome pathways potentially bridging pathogenesis of COVID-19. Preprints, 2021010065. doi:10.20944/preprints202101.0065.v1

Kinaret, P. A. S., del Giudice, G. and Dario, G. (2020). Covid-19 acute responses and possible long term consequences: What nanotoxicology can teach us. Nano Today 35, 100945. doi:10.1016/j.nantod.2020.100945

Nymark, P., Sachana, M., Leite, S. B. et al. (2021). Systematic organization of COVID-19 data supported by the adverse outcome pathway framework. Front Public Health 9, 938605. doi:10.3389/fpubh.2021.638605

Polak, S. B., Van Gool, I. C., Cohen, D. et al. (2020). A systematic review of pathological findings in COVID-19: A pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol 33, 2128-2138. doi:10.1038/s41379-020-0603-3

Rai, B., Shukla, A. and Dwivedi, L. K. (2021). Estimates of serial interval for COVID-19: A systematic review and meta- analysis. Clin Epidemiol Glob Health 9, 157-161. doi:10.1186/s12879-021-05950-x

Villeneuve, D. L., Crump, D., Garcia-Reyero, N. et al. (2014). Adverse outcome pathway (AOP) development I: Strategies and principles. Toxicol Sci 142, 312-320. doi:10.1093/toxsci/kfu199

Villeneuve, D. L., Landesmann, B., Allavena, P. et al. (2019). Representing the process of inflammation as key events in adverse outcome pathways. Toxicol Sci 163, 346-352. doi:10.1093/toxsci/kfy047

Vinken, M. (2013). The adverse outcome pathway concept: A pragmatic tool in toxicology. Toxicology 312, 158-165. doi:10.1016/j.tox.2013.08.011

Wang, F., Qu, M., Zhou, X. et al. (2020). The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China. J Transl Med 18, 270. doi:10.1186/s12967-020-02423-8

Wittwehr, C., Amorim, M. J., Clerbaux, L.-A. et al. (2021). Understanding COVID-19 through adverse outcome pathways – 2nd CIAO AOP design workshop. ALTEX 38, 351-357. doi:10.14573/altex.2102221

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>